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Abstract
Introduction: Bioluminescence imaging, especially planar bioluminescence imaging, has been
extensively applied in in vivo preclinical biological research. Bioluminescence tomography (BLT)
has the potential to provide more accurate imaging information due to its 3D reconstruction
compared with its planar counterpart.
Methods: In this work, we introduce a positron emission tomography (PET) radionuclide
imaging-based strategy to validate the BLT results. X-ray computed tomography, PET,
spectrally resolved bioluminescence imaging, and surgical excision were performed on a tumor
xenograft mouse model expressing a bioluminescent reporter gene.
Results: With different spectrally resolved measured data, the BLT reconstructions were acquired
based on the third-order simplified spherical harmonics (SP3) approximation and the diffusion
approximation (DA). The corresponding tomographic images were obtained for validation of
bioluminescence source reconstruction.
Conclusion: Our results show the strength of PET imaging compared with other validation
methods for BLT and improved source localization accuracy based on the SP3 approximation
compared with the diffusion approximation.
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Reconstruction algorithm
Introduction
O
ptical molecular imaging, especially planar biolumi-
nescence and fluorescence imaging, has been exten-
sively applied in preclinical research, particularly with small
animal models such as genetically modified mice and
murine tumor xenografts. Tomographic optical molecular
imaging localizes the source position and should provide
more accurate biological information compared to its planar
counterpart [1]. The possibility and potential of biolumines-
cence tomography (BLT) [2, 3] and fluorescence molecular
tomography as standalone imaging modalities have been
investigated using phantoms and mouse experiments [4, 5].
To develop a practical, accurate, and robust BLT system,
more factors need to be investigated, such as in vivo
validation strategies and more precise reconstruction algo-
rithms among others. To validate the optical source
information, physical and in vitro methods are commonly
used in phantom- and nonbiological mouse-based experi-
ments. In vivo imaging strategies, such as computed
tomography (CT), are also used to validate artificial
source-based optical experiments [6]. Due to the poor soft
tissue contrast in preclinical CT imaging, it is difficult to
identify the optical source in vivo based on anatomical
information only. New in vivo validation strategies are
necessary to develop tomographic optical molecular imaging.
In the transition from phantom-based feasibility investigations
Correspondence to: Arion F. Chatziioannou; e-mail: archatziioann@
mednet.ucla.eduto in vivo biological research, several assumptions affect
source reconstruction quality [7]. Although the diffusion
approximation (DA) has been widely used, the method
becomes inaccurate when the bioluminescence sources are
near the surface, or in tissues with high and anisotropic
absorption [7, 8]. This inaccuracy leads to reduced informa-
tion acquired from bioluminescence sources. Reconstruction
algorithms based on high-order approximations to the
radiative transfer equation (RTE) should improve these results
and need to be further developed [8]. In addition, ap r i o r i
information, such as spectrally resolved measurements [9, 10]
and permissible source region [11], is indispensable to
constrain the possible solutions in BLT reconstruction.
Inthispaper,aninvivovalidationstrategybasedonpositron
emission tomography (PET) is proposed for tomographic
bioluminescence imaging. An in vivo mouse experiment was
performed with a luciferase-based tumor xenograft. After
acquiring multiple spectral optical data, the bioluminescence
source was localized with SP3- and DA-based reconstruction
algorithms and compared to PET and CT acquired data. The
reconstructed results not only show the advantages of PET-
based in vivo validation compared with traditional CT-based
methodsbutalsodemonstratetheeffectivenessandpotentialof
the SP3-based BLT reconstruction algorithm.
Materials and Methods
In the experiment, three types of imaging modalities, that is, X-ray
CT, PET, and optical imaging, were used. To maintain the animal
in the same position throughout the whole procedure, a glass holder
was fabricated to support the mouse. To realize multi-view
detection, two mirrors were used to acquire the photon distribution
from two side views. A murine tumor cell line, MC38fluc,
transfected to provide constitutive expression of firefly luciferase,
was used to generate a tumor xenograft in the abdomen of a nude
mouse and allowed to develop for 3 weeks. To perform the imaging
experiments, the animal was anesthetized and injected with the
optical substrate (luciferin). Optical data was gathered 10 min after
substrate administration using the Maestro 2 in vivo Imaging
System (CRI, Woburn, MA, USA). The filter bandpass width was
set to 20 nm, and optical data at four wavelengths (600, 620, 640,
and 660 nm) was collected. The exposure time for each wavelength
was 5 min. Fig. 1a shows a mouse photograph and the
corresponding optical data at 660 nm. The image signal-to-
noise ratio (SNR) ranged from 6.81 to 7.27 (SNR was calculated
by Savg/Navg at four wavelengths, where Savg and Navg are the
averages of the image signal and noise). Since the optical signals
are weak and the sensitivity of this particular detection system is
low, the image SNR is low. However, the nature of the optical filter
[12] allowed the photon distribution on the mouse surface to be
observed for arbitrary wavelength bands. Because the tumor
position after 3 weeks was very close to the mouse abdomen, the
photon distribution could not be acquired from the two side views.
After finishing the bioluminescence optical signal acquisition, the
PET tracer (
18F-fluorodeoxy-glucose (
18F-FDG)) was injected
intravenously into the mouse. After 1 h uptake, the animal was
imaged using a microCT and a high resolution preclinical PET
system (Siemens Preclinical Solutions, Knoxville, TN, USA) to
obtain the CT and PET images shown in Fig. 1b, c. Localization of
the tumor position from the PET images is facilitated due to the
high
18F-FDG uptake compared to background. However, the same
is not true when analyzing the CT images due to the similar density
contrast between the tumor and other tissues in the animal
abdomen. These data clearly show the advantages of PET imaging
for in vivo optical imaging validation. After all the collection of the
imaging data, the mouse was euthanized and dissected to confirm
the tumor location. A tumor mass of approximately 3 mm diameter
was found attached to the small intestine, shown in Fig. 1d.T o
realize the spectrally resolved BLT reconstruction with the high-
order approximations to the RTE, we have developed a fully
parallel reconstruction framework with the simplified spherical
harmonics approximation (SPN)[ 13]. Regarding the SP3 approx-
imation, its mathematical model and boundary formula are [14]
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Fig. 1. Imaging of a xenograft tumor in a nude mouse. The photograph is used to map the optical data from the CCD camera
onto the surface of the volumetric mesh; the computed tomography slice shows the same position cross-section with the
positron emission tomography scan; dissection is used to further confirm the tumor position.
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where μan=μs(1−g
n)+μa(n=1, 2, 3), φi(i=1, 2) are the composite
moments relevant to the Legendre moments, μs and μa are the
scattering and absorption coefficients, and S is the bioluminescence
source. Note that μan, φi, and S depend on the wavelength when
spectrally resolved measured data is acquired. The coefficients
A1,...,D1,...,A2,...,D2 can be calculated using the formulas in [14].
Furthermore, the exiting partial current J
+ on the mouse surface is
obtained:
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where the coefficients J0,...,J3 can also be calculated based on the
relevant formulas in [14]. Note that SP1 (DA) can be obtained
correspondingly by setting φ2=0. After a series of deductions, a
simple relationship between the measurable boundary data and the
unknown source distribution is established:
Jþ;b ¼ ASp ð4Þ
where
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where K is the number of the used wavelengths, γk is the percentage
at the wavelength λk of the total energy, and G(λk)i st h e
relationship matrix between the permissible source region S
p and
the measurable data J
+,b at the wavelength λk.T h es u r f a c e
measured data J
+,m corresponding to J
+,b leads to a reconstruction
failure when solving Eq. 4 directly due to the presence of noise. We
can solve the bound-constrained least squares problem
min0GS
pGS
sup  Sp ðÞ : ASp   Jþ;m jj jj
2 ð5Þ
where S
sup is the upper bound of the source density. By minimizing
the objective function Θ(S
p), BLT reconstruction becomes possible.
Here, the limited memory variable metric bound-constrained quasi-
Newton method (BLMVM) is used for BLT reconstruction [15].
Results
With respect to the photon distribution on the mouse surface,
the volumetric mesh of half the mouse body shown in Fig. 2
was generated using the commercial software Amira 3.0
(Mercury Computer Systems, Inc. Chelmsford, MA, USA).
Since the photon distribution can only be obtained from the
ventral view and the photon propagation path is almost
totally consisted of muscle tissue, we assumed that the
reconstructed domain was homogeneous with muscle tissue.
Fig. 2. The volumetric mesh used in bioluminescence tomography reconstruction and the photon distribution at 660 nm. The
red lines are used to show the permissible source region.
Table 1. Optical properties of actual mouse muscle [7]
Wavelength 600 nm 620 nm 640 nm 660 nm
μa(λ) (mm
−1) 0.187 0.107 0.088 0.08
μs(λ) (mm
−1) 9.29 9.22 9.13 9.02
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average element of 1.2 mm diameter. The assumed optical
properties of mouse muscle are shown in Table 1.T o
constrain the BLT solution, a permissible source region with
5,965 discretized points was selected, that is S
p={(x,y,z)|
33.0GyG55.0 mm, (x,y,z) ∈ Ω}, where Ω is the entire
domain, as shown in Fig. 2. The acquired optical data was
mapped onto the mesh surface after manual co-registration
between the mesh and the mouse photograph in Amira. The
differences of the optical properties at different wavelengths
SP3-based
DA-based
Fig. 3. Imaging validation and bioluminescence tomography reconstruction comparison between SP3- and DA-based models.
The dashed lines are used to align the boundaries of optical cross-sections with the corresponding computed tomography
slices; the red lines show the center of tumor on positron emission tomography images.
Fig. 4. DA- and SP3-based bioluminescence tomography reconstruction comparisons with different spectrally resolved
measurements. 1W, 2W, and 4W denotes that one (660 nm), two (600 and 660 nm), and four wavelengths are used. Cross-
sections with blue and red boundaries are the center position of the actual and reconstructed sources, respectively. The
volumetric mesh denotes reconstructed values larger than 10% of the reconstructed maximum.
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properties at 600 and 660 nm have a large difference (as
shown in Table 1), Fig. 3 shows the SP3- and DA-based
reconstruction results when using 1,072 measured points and
these two wavelengths. Through comparison between
optical and PET reconstructed results, one can determine
that the source location errors of SP3-based reconstruction
are less than 1.5 mm at each direction. However, the DA-
based BLT reconstruction is not as accurate. In the depth
direction, the location errors are about 4 mm. Note that the
background noise is very high due to nonspecific probe
uptake in PET imaging. This reconstruction comparison
shows the effectiveness of the SP3-based reconstruction
algorithm for BLT. To further confirm the effect of
spectrally resolved measured data, BLT reconstructions
using measurements in one and four wavelengths were
performed. The reconstructed results are shown in Fig. 4.
Due to the absence of source depth information when using
one wavelength, poor reconstruction results were obtained.
However, when four wavelengths were used, the localization
of the source center was not improved; instead, there were
some artifacts in the reconstructed results compared with
two wavelengths. Small differences in the optical properties
between 620, 640, and 660 nm reduced the benefits from
multispectral measured data, while the noise effects in the
measured data became significant. Although the use of
multispectral data can improve reconstructed image quality,
in principle, the results are a trade-off between photon
sensitivity (presence of statistical noise) and differences
between optical properties.
Discussions and Conclusion
To the best of the authors' knowledge, this contribution
represents the first time that PET imaging has been used for
in vivo BLT imaging validation. The results show the
effectiveness of radionuclide imaging and the potential of
high-order approximation models for BLT reconstruction.
Further research will focus on mouse experiments with
disease models. In using BLT with these models, validation
with FDG-PET may not always be possible if the target
tissue does not demonstrate adequate image contrast. For
this purpose, we will be utilizing genetically modified mouse
models in which target tissues for bioluminescent imaging
are expressing both a bioluminescence-based reporter gene
and a PET probe/PET reporter gene [16].
Although the simulated and experimental [17] SPN-based
BLT reconstruction algorithm provides improved local-
ization precision of the bioluminescent source, the sen-
sitivity of the detection system of BLT plays a very
important role in BLT reconstruction for experimental
reconstructions. With the increase of the tumor depth, the
optical signals on the surface of the mouse are signifi-
cantly attenuated. More sensitive detection systems become
n e c e s s a r yt oi m p r o v ei m a g er e c onstruction. A new Optical-
PET (OPET) imaging system [18] provides not only the
simultaneous detection of optical signals and gamma rays
but also higher sensitivity due to the natural multi-view
detection mode and the photon collection from larger solid
angle. More experiments will be performed on the OPET
system, and relevant results will be reported in the future,
especially on the effect of signal loss, image reconstruction,
and sensitivity for the methodology.
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